Skip to Content
Democrats Tout Federal… image

Democrats Tout Federal Patent Take-Backs for Lowering Drug Costs


Valerie Bauman, quoting Rachel Sachs (Academic Fellow Almumna)
Bloomberg Law

From the article: “March-in rights hasn’t been used before, so it’s hard to know what it would look like in practice,” said Rachel Sachs,…

The House Passed Its… image

The House Passed Its Prescription Drug Plan — Here’s What’s In It


Selena Simmons-Duffin
NPR

From the article: Right now, drugmakers can raise the price of a drug as much as they want, whenever they want, as long as the market can bear it. Under…

First Opinion: Do… image

First Opinion: Do large pharma companies provide drug development innovation?: Our analysis says no


Emily H. Jung (former intern), Alfred Engelberg, and Aaron S. Kesselheim
STAT

From the article: Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug…

Harvard Law School… image

Harvard Law School researchers call for more regulation in medical AI


Andrea Park, referencing work by Sara Gerke (Research Fellow, Medicine, Artificial Intelligence, and Law) and I. Glenn Cohen (Faculty Director)
Becker's Health IT & CIO Report

From the article: Existing safeguards from the FDA and other regulatory bodies will require significant updates in order to maintain safety and ethics in healthcare's use of constantly "…

Researchers call on… image

Researchers call on regulators to reduce risks of AI in medicine


Greg Slabodkin, referencing work by Sara Gerke (Research Fellow, Medicine, Artificial Intelligence, and Law) and I. Glenn Cohen (Faculty Director)
Health Data Management

From the article: Continuous monitoring is critical if regulatory agencies such as the Food and Drug Administration are to reduce the risk in artificial and machine learning-based medical technology. That…

Inside Tennessee’s… image

Inside Tennessee’s Final 1115 Medicaid Block Grant Proposal


Sara Rosenbaum Alexander Somodevilla Morgan Handley Rebecca Morris referencing work by Rachel Sachs(Academic Fellow Alumna)
Health Affairs

From the article: The state’s response to comments in general seeks to provide general assurances that it intends to strengthen TennCare, not harm it. Perhaps most notable is…

Will sky-high drug… image

Will sky-high drug prices spur the US to use an obscure power over patents?


Jonathan Gardner, quoting Rachel Sachs (Academic Fellow Alumna)
BiopharmaDive

From the article: The problem with appealing to march-in rights as a solution is the government has always refused to use the power it holds — as the Genzyme case…

White House report on… image

White House report on Pelosi drug-pricing bill flawed, health policy experts say


Donna Young, quoting Rachel Sachs (Academic Fellow Almumna)
S&P Global Market Intelligence

From the article: Rachel Sachs, an associate professor of law at Washington University in St. Louis, noted that most of the economic logic the White House used would apply to…

Analysts Predict IPI… image

Analysts Predict IPI and Senate Bill Unlikely to Impact Drug Industry Like Pelosi Bill


Zachary Brennan, quoting Rachel Sachs (Academic Fellow alumna)
Regulatory Focus

From the article: Rachel Sachs, associate professor of law at Washington University in St. Louis, told Focus that she agreed with the general findings of the report, adding: “In…

How a Democratic… image

How a Democratic president could reduce drug prices without Congress


Dylan Scott, quoting Rachel Sachs (Academic Fellow alumna)
Vox

From the article: It has been sitting on the shelf for a long time for a reason. But the Yale authors make the case that there is strong precedent for…